Cue Biopharma Inc (NAS:CUE)
$ 1.62 -0.03 (-1.82%) Market Cap: 78.80 Mil Enterprise Value: 52.23 Mil PE Ratio: 0 PB Ratio: 2.61 GF Score: 52/100

Q2 2022 Cue Biopharma Inc Earnings And Business Update Call Transcript

Aug 23, 2022 / 08:30PM GMT
Release Date Price: $3.22 (+5.57%)
Operator

Greetings, and welcome to the Cue Biopharma update call. (Operator Instructions). As a reminder, this conference is being recorded.

I would now like to turn this conference over to Mr. Dan Passeri, Cue Biopharma's Chief Executive Officer. Thank you, sir. You may begin.

Daniel R. Passeri
Cue Biopharma, Inc. - CEO & Director

Okay. Thank you, and good afternoon, everyone. Just to remind you, as we proceed through the presentation, we'll convey which slide we're on, and you can advance the slides directly. We appreciate your time and interest in our update call regarding our ongoing trials of CUE-101 as well as CUE-102, our initial representative drug candidates of the IL-2-based CUE-100 series.

Joining me on today's call is Dr. Anish Suri, our President and Chief Scientific Officer; Dr. Ken Pienta, our Acting Chief Medical Officer; and Dr. Matteo Levisetti, our Senior Vice President of Clinical Development; and Kerri Millar, our Chief Financial Officer. This conference is being recorded and will be available on our website for the next 30

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot